HIV/AIDS
Fusion inhibitors effective in HIV patients able to maintain virological control
Published in AIDS Weekly, July 5th, 2004
"The number of antiretroviral-experienced HIV patients with multiple resistances against the currently available antiretroviral drug classes is increasing substantially. Therapeutic options for this specific group of patients are limited," wrote scientists in the Journal of Antimicrobial Chemotherapy.
"The fusion inhibitor enfuvirtide represents the first new therapeutic option from a new drug class for this patient population. An optimized background therapy with remaining antiviral activity appears essential in order to avoid resistance development...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-07-05)
More Articles from AIDS Weekly
- Diagnostics
New strategies detect HIV earlier and more effectively than ever - HIV/AIDS Dementia
International study will evaluate neurological disease in HIV/AIDS patients - HIV/AIDS Research
HIV viral load rebounders have limited long-term naive CD4+ cell reconstitution - HIV/AIDS Therapy
Bis-anthracycline antibiotics inhibit HIV-1 transcription - Regulatory Issues
WHO removes two drugs from list of approved HIV medicines - AIDS Therapy
Uganda begins distributing free generic AIDS drugs - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
